A deep-dive into our hypoxia-responsive Zr-AZB MOF: how it encapsulates drugs, senses tumor oxygen levels, and releases payload directly at the tumor site — no external activation required.
A Metal-Organic Framework (MOF) is a crystalline, three-dimensional porous material assembled from metal ion clusters connected by organic linker molecules. Think of it as a molecular cage — extraordinarily regular, infinitely tunable, and capable of hosting guest molecules inside its pores.
What makes MOFs revolutionary for drug delivery is their combination of properties that no other material class achieves simultaneously: ultrahigh surface area, tunable pore geometry, chemical responsiveness, and biocompatibility.
Zr-AZB MOF structure — nodes (teal), azo-bond linkers (gold), drug payload (center)
Solid tumors — pancreatic, breast, lung, liver — develop oxygen-depleted cores called hypoxic microenvironments. This is one of oncology's most intractable problems, and it's why so many promising drugs fail in the clinic.
Conventional chemotherapy loses efficacy — many drugs rely on reactive oxygen species (ROS) to kill cells. In hypoxic regions, there's no oxygen to generate ROS.
Systemic toxicity limits dose escalation — drugs released throughout the body harm healthy tissue before reaching hypoxic tumor cores.
Hypoxic cells upregulate resistance genes — HIF-1α pathway activation makes tumors progressively harder to treat with conventional approaches.
No existing approved system exploits hypoxia itself as the release trigger — turning the tumor's defining feature from a shield into a vulnerability.
Viva Bio's Answer
The Zr-AZB MOF turns hypoxia from a clinical barrier into a molecular trigger. The lower the oxygen, the more efficiently the system releases drug — delivering maximum dose precisely where it's needed most.
From synthesis to tumor-selective drug release, every step is mechanistically validated by PXRD, IR spectroscopy, BET analysis, and 72-hour in vitro kinetics data.
Zirconium tetrachloride and (E)-4,4'-(diazene-1,2-diyl)dibenzoic acid (the Z1 azobenzene linker) are combined in DMF at 100°C for 5 days. The resulting orange crystalline Zr-AZB MOF (Y1) has a 3D porous architecture with octahedral and tetrahedral cavities. Cisplatin is encapsulated via 48-hour incubation at 37°C, 200 RPM — yielding 44–47% drug loading and up to 89% encapsulation efficiency.
In oxygenated tissue (5–21% O₂), cellular reducing agents such as NADH and FADH₂ are present — but oxygen is also abundant. When these reducing agents donate electrons, molecular O₂ acts as the preferred electron acceptor, forming a superoxide anion (O₂•⁻). The azo (N=N) bond within the MOF linker is spared. The MOF structure remains crystalline and intact, protecting the drug payload during circulation.
As the MOF nanoparticle (100 ± 20 nm) accumulates in the tumor via the enhanced permeability and retention (EPR) effect, it enters the hypoxic core where O₂ concentration drops to 0.02–2% and pH falls (acidic microenvironment). Now, when NADH and FADH₂ — activated by tumor enzymes azoreductase and NQO1 — donate electrons, there is insufficient O₂ to intercept them. The azo bond becomes the primary electron acceptor.
The reducing agent donates one electron to one nitrogen of the N=N azo bond, forming a radical anion intermediate. This species undergoes protonation in the acidic tumor environment to form a hydrazo intermediate (–NH–NH–). The hydrazo intermediate is thermodynamically unstable and undergoes rapid N–N bond cleavage, generating two amine radicals. These rapidly react with available protons to form stable amine (–NH₂) compounds, completing the reduction.
Cleavage of the azo bond destroys the integrity of the organic linker that holds the MOF together. Without a functioning bridging linker, the Zr(IV) metal nodes lose their coordinative support and the entire 3D crystalline framework collapses. Drug molecules previously encapsulated within the pores are released directly into the tumor microenvironment. PXRD shows characteristic peak loss beginning at 1 hour under hypoxia — the structural collapse is irreversible.
The N=N azo bond is the molecular switch at the heart of the platform. Its reduction proceeds through four distinct, characterised intermediates — each confirmed by spectroscopic data.
The second patent family (CWY002) adds a real-time oxygen sensing layer. Phosphorescent Cu(I) complexes of formula [Cu(TPYM)(L)]⁺ — where TPYM is Tris(2-pyridyl)methane and L is a monophosphine ligand — emit at 443 nm and undergo oxygen-concentration-dependent phosphorescence quenching.
This allows non-invasive, quantitative mapping of intratumoral oxygen tension — independently of and complementary to the drug release mechanism. Together they form a closed-loop theranostic: the system senses hypoxia and releases drug simultaneously.
Cu⁺ absorbs light → S₀ → S₁ (singlet excited) → intersystem crossing (ISC) → T₁ (triplet). In absence of O₂: long phosphorescence lifetime, bright emission. In presence of O₂: triplet excited state quenched via energy transfer → singlet oxygen (¹O₂) generated → emission intensity drops proportionally.
Phosphorescence quenching of [Cu(TPYM)(P(o-tol)₃)]PF₆ (X1) in PBS:MeOH (8:2). QY = 8.19%.
Cisplatin · MW 300.05 · Cl₂H₆N₂Pt · 5 mg/mL solubility · 37°C · 200 RPM · 48 hr · UV-Vis analysis
| Sample | Encapsulated | DL% | EE% |
|---|---|---|---|
| Sample 1 | 3.91 mg | 43.87% | 78.15% |
| Sample 2 | 4.43 mg | 46.99% | 88.66% |
| Sample 3 | 4.38 mg | 46.71% | 87.65% |
| Timepoint | Normoxia | Hypoxia | Fold Δ |
|---|---|---|---|
| 30 min | 0.175 mg | 1.537 mg | 8.8× |
| 2 hr | 0.356 mg | 2.626 mg | 7.4× |
| 6 hr | 0.522 mg | 3.278 mg | 6.3× |
| 24 hr | 0.965 mg | 4.117 mg | 4.3× |
| 48 hr | 1.647 mg | 4.778 mg | 2.9× |
| 72 hr | 2.306 mg | 5.422 mg | 2.4× |
The same oxygen-sensing platform that detects hypoxic tumors also detects the respiratory depression caused by opioid overdose. When opioids suppress breathing, blood oxygen drops rapidly — triggering an identical sensing and release cascade to deliver Narcan (naloxone) autonomously.
| Parameter | Value |
|---|---|
| Metal centre | Zr(IV) |
| Linker | (E)-4,4'-(diazene-1,2-diyl)dibenzoic acid (Z1) |
| Synthesis | ZrCl₄ + Z1 in DMF, 100°C, 5 days |
| Morphology | Spherical |
| Particle size | 100 ± 20 nm (TEM/SEM) |
| BET surface area | 83.028 m²/g |
| N₂ sorption temp. | 77.360 K |
| Pore volume method | DFT from N₂ isotherm |
| pH stability | 1–11 (PXRD confirmed) |
| PBS stability | Stable (1× PBS, multiple timepoints) |
| Drug loading (cisplatin) | 43.87 – 46.99% |
| Encapsulation efficiency | 78.15 – 88.66% |
| Loading conditions | 37°C, 200 RPM, 48 hr, UV-Vis |
| PXRD hypoxia onset | 1 hr (structural degradation begins) |
| PXRD normoxia | Crystalline (stable throughout) |
| N=N IR stretch (Z1) | 1425 cm⁻¹ |
| C=O IR (Z1) | 1690 cm⁻¹ |
| C=O IR (Y1 MOF) | 1600 cm⁻¹ |
| Parameter | Value |
|---|---|
| Formula | [Cu(TPYM)(P(o-tol)₃)]PF₆ |
| TPYM ligand | Tris(2-pyridyl)methane |
| Phosphine ligand | Tri(o-tolyl)phosphine |
| Excitation max (X1) | 260 nm |
| Emission max (X1) | 443 nm |
| Solvent (X1) | PBS:MeOH (8:2) |
| Quantum yield (X1) | 8.19% |
| Quenching at 10% O₂ / 1 hr | 75% |
| Quenching at 20% O₂ / 1 hr | 82% |
| Quenching at 100% O₂ / 1 hr | 74% |
| In vivo activation duration | Up to 12 hours (no excitation) |
| Emission mechanism | TADF (S₁ → T₁ → quench) |
| X12 MOF (20% O₂ / 20 min) | 85% quenching |
| Zn-An₂Py polymer (Y2) | QY 43%, emission 570 nm |
| Coord. polymer formula | [Zn₂(benzoate)₄(An₂Py)₂] |
| Ligand systems (total) | 19 novel compounds |
| Emission range | Tunable 300–800 nm |